Bioreduction in the Activation of Drugs
Proceedings of the Second Biochemical Pharmacology Symposium, Oxford, UK, 25-26 July 1985
Published on 22. October 2013
128 pages
978-1-4831-9083-9 (ISBN)
Description
Bioreduction in the Activation of Drugs covers the proceedings of the Second Biochemical Pharmacology Symposium. The book presents papers that cover the applications of bioreduction in drug activation, along with its concerns. The text first presents materials about enzymology, such as overview of enzyme systems involved in bioreduction of drugs and in redox cycling, and reductive role of glutathione in the redox cycling of oxidizable drugs. Next, the book covers papers on bacterial and parasites infection, which include reduction by the gut microflora of animals and human and reduction of nitroimidazoles in vitro and DNA damage. The remaining articles deal with cancer treatment, such as hypoxia-mediated nitro-heterocyclic drugs in the radio- and chemotherapy of cancer, and the biological properties of reduced nitroheterocyclics and possible underlying biochemical mechanisms. The text will be of great use to researchers and practitioners of medicine, pharmacology, and biochemistry.
More details
Other editions
Additional editions
Book
01/1986
Pergamon
€38.38
Article exhausted; check different version
Content
Session A: Enzymology Overview of Enzyme Systems Involved in Bioreduction of Drugs and in Redox Cycling Regulation of Reductive Processes by Glutathione The Crucial Role of Low Steady State Oxygen Partial Pressures in Haloalkane Free-Radical-Mediated Lipid Peroxidation. Possible Implications in Haloalkane Liver Injury Short Communications Reductive Role of Glutathione in the Redox Cycling of Oxidizable Drugs Generation of Photoemissive Species During Quinone Redox Cycling Chairman's SummarySession B: Bacterial and Parasite Infections Reduction by the Gut Microflora of Animals and Man The Metabolic Activation of Ronidazole[(L-Methyl-5-Nitroimidazole- 2-Yl)-Methyl Carbamate] to Reactive Metabolites by Mammalian, Cecal Bacterial and T. Foetus Enzymes Reductive Activation of Nitroimidazoles in Anaerobic Microorganisms Comparing the Reduction of Nitroimidazoles in Bacteria and Mammalian Tissues and Relating it to Biological Activity Reduction of Nitroimidazoles in Vitro and DNA Damage Short Communications In Vitro Reductive Activation of Nitroimidazoles Inhibition of Hydrogen Production in Drug-Resistant and Susceptible Trichomonas Vaginalis Strains by a Range of Nitroimidazole Derivatives The Role of the Gut Flora in the Reduction of Sulphoxide Containing Drugs Chairman's SummarySession C: Role in Treatment of Cancer-Part I The Role of Mitomycin Antibiotics in the Chemotherapy of Solid Tumors Hypoxia-Mediated Nitro-Heterocyclic Drugs in the Radioand Chemotherapy of Cancer. An Overview Biochemistry Of Reduction of Nitro Heterocycles Short Communications Short Communications Toxicity of Oxygen at Atmospheric Concentration for Newly Explanted Cancer Cells The Effect of Bioreduction on the Oncogenicity of Nitroimidazoles Chairman's SummarySession D: Role in Treatment of Cancer-Part II The Biological Properties of Reduced Nitroheterocyclics and Possible Underlying Biochemical Mechanisms RSU 1069, A Nitroimidazole Containing an Aziridine Group. Bioreduction Greatly Increases Cytotoxicity Under Hypoxic Conditions Sensitization of Cancer Chemotherapeutic Agents by Nitroheterocyclics Short Communication Benznidazole: Nitroreduction and Inhibition of Cytochrome P-450 in Chemosensitization of Tumour Response to Cytotoxic Drugs Chairman's Summary
